1-14 of 14
Jean-Francois Larouche
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Adam Suleman, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, Michael Sebag, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Heidi Simmons, Monica Gallucci, George A. Tomlinson, Neil Berinstein
Journal: Blood
Blood (2024) 144 (Supplement 1): 6291.
https://doi.org/10.1182/blood-2024-203317
Published: 2024
Journal Articles

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Neil Berinstein, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Monica Gallucci, Heidi Simmons
Journal: Blood
Blood (2023) 142 (Supplement 1): 3037.
https://doi.org/10.1182/blood-2023-186347
Published: 2023
Journal Articles

Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial

Diego Villa, Jean-Francois Larouche, Matthew C. Cheung, Mary-Margaret Keating, Katherine Zukotynski, Petter Tonseth, Samantha Mayo, Robert Laister, David W. Scott, John Kuruvilla
Journal: Blood
Blood (2023) 142 (Supplement 1): 3042.
https://doi.org/10.1182/blood-2023-179375
Published: 2023
Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Clinical Trials & Observations
Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten
Journal: Blood
Blood (2022) 140 (21): 2248–2260.
https://doi.org/10.1182/blood.2022015478
Published: 2022
Includes: Supplemental data
Journal Articles

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Maria Murphy, Mathilde Fromentin, Julie Campeau, Michael Sebag, Félix Couture, Jean-François Larouche, Christopher Lemieux, Silvy Lachance, Sandra Cohen, Luigina Mollica, Olivier Veilleux, Isabelle Fleury
Journal: Blood
Blood (2022) 140 (Supplement 1): 13228–13229.
https://doi.org/10.1182/blood-2022-156473
Published: 2022
Journal Articles

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Douglas A. Stewart, Lois E. Shepherd, Jill J. Dudebout, Jean-François Larouche, Neil Chua, Tara Baetz, Michael Crump, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Deborah Marcellus, Pamela Skrabek, Jesse Kelly, Annette E. Hay, Bingshu Chen, John Kuruvilla
Journal: Blood
Blood (2022) 140 (Supplement 1): 3734–3736.
https://doi.org/10.1182/blood-2022-163706
Published: 2022
Journal Articles

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Neil L Berinstein, Gail Klein, Katerina Welsh, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed A Aljama, Jean-François Larouche
Journal: Blood
Blood (2022) 140 (Supplement 1): 9383–9384.
https://doi.org/10.1182/blood-2022-169245
Published: 2022
Journal Articles

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean Marc Schiano De Colella, Hervé Tilly, M. Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward Libby, Rene-Olivier Casasnovas, Ian W. Flinn, Corinne Haioun, Herve Maisonneuve, Loic Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas Daguindau, Vincent Delwail, Gian-Matteo Pica, Alejandro Martin Garcia-Sancho, Armando Lopez-Guillermo, Jean-Francois Larouche, Kiyoshi Ando, Gomes da Silva Maria, Marc André, Ka Lung Wu, Laurie H. Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan H. Fowler, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 2417.
https://doi.org/10.1182/blood-2021-148218
Published: 2021
Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Christina To, Marie José Kersten
Journal: Blood
Blood (2021) 138 (Supplement 1): 430.
https://doi.org/10.1182/blood-2021-147598
Published: 2021
Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Clinical Trials & Observations
Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Robin Gasiorowski, Richard Greil, Árpád Illés, Nathalie A. Johnson, Jean-François Larouche, Pieternella J. Lugtenburg, Caterina Patti, Gilles A. Salles, Marek Trněný, Sven de Vos, Farheen Mir, Divya Samineni, Su Y. Kim, Yanwen Jiang, Elizabeth Punnoose, Arijit Sinha, Emma Clark, Nathalie Spielewoy, Kathryn Humphrey, Alexandra Bazeos, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 137 (5): 600–609.
https://doi.org/10.1182/blood.2020006578
Published: 2021
Includes: Supplemental data
Journal Articles

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Edith Julia, Nathan H Fowler, MD, Emmanuel Bachy, MD PhD, Pierre Feugier, MD PhD, Reda Bouabdallah, Herve Tilly, MD PhD, M. Lia Palomba, MD, Christophe Fruchart, MD, Edward N. Libby, III, MD, Rene-Olivier Casasnovas, MD, Ian W. Flinn, MD PhD, Corinne Haioun, MD PhD, Herve Maisonneuve, MD, Loic Ysebaert, MD PhD, Nancy L. Bartlett, MD, Kamal Bouabdallah, MD, Pauline Brice, Vincent Ribrag, MD, Nicolas Daguindau, MD, Steven Le Gouill, Gian-Matteo Pica, MD, Alejandro Martín, MD PhD, Armando Lopez-Guillermo, Jean-Francois Larouche, MD, Kiyoshi Ando, Gomes da Silva Maria, MD PhD, Marc André, Ka Lung Wu, MD, Laurie H Sehn, MD, Kensei Tobinai, MD PhD, Guillaume Cartron, Richard Delarue, Myron Czuczman, Luc Xerri, MD PhD, Gilles A. Salles, MD PhD, Franck Morschhauser, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1524.
https://doi.org/10.1182/blood-2019-129024
Published: 2019
Journal Articles

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Franck Morschhauser, Pierre Feugier, Ian W. Flinn, MD PhD, Robin E Gasiorowski, Richard Greil, MD, Árpád Illés, Nathalie A Johnson, MDPhD, Jean-Francois Larouche, Pieternella J Lugtenburg, Caterina Patti, Gilles Salles, MD PhD, Marek Trněný, Sven de Vos, Farheen Mir, MBBS, Martin Kornacker, Elizabeth A Punnoose, Divya Samineni, Edith Szafer-Glusman, Adam Petrich, Arijit Sinha, Mehrdad Mobasher, MD MPH, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 782.
https://doi.org/10.1182/blood-2018-99-118519
Published: 2018
Journal Articles

Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL)

Antonio Salar, MD, Irit Avivi, MD, Jean-Francois Larouche, MD, Andrea Janikova, MD, PhD, Juliana Pereira, PhD, Mike Brewster, Olivier Catalani, Christine McIntyre, Pakeeza Sayyed, Andrew Haynes
Journal: Blood
Blood (2012) 120 (21): 1641.
https://doi.org/10.1182/blood.V120.21.1641.1641
Published: 2012
Journal Articles

Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab

Jean-Francois Larouche, MD, Marc Bergeron, MD, Grace Hampson, Tim Illidge, Robert Delage, MD, MSc, FRCP
Journal: Blood
Blood (2011) 118 (21): 1644.
https://doi.org/10.1182/blood.V118.21.1644.1644
Published: 2011